General Information


We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. We focus our efforts on targeting and modulating N-methyl-D-aspartate receptors, or NMDArs, which are vital to normal and effective function of the brain and nervous system. We believe leveraging the therapeutic advantages of the differentiated modulatory mechanism of our compounds will drive a paradigm shift in the treatment of disorders of the brain and nervous system.

Employees: 64
Founded: 2015
Contact Information
Address 909 Davis Street, Suite 600, Evanston, IL 60201, US
Phone Number (847) 871-0377
Web Address https://www.aptinyx.com
View Prospectus: Aptinyx
Financial Information
Market Cap $520.6mil
Revenues $6.28 mil (last 12 months)
Net Income $-35.0 mil (last 12 months)
IPO Profile
Symbol APTX
Exchange NASDAQ
Shares (millions): 6.4
Price range $16.00 - $16.00
Est. $ Volume $102.4 mil
Manager / Joint Managers J.P. Morgan/ Cowen/ Leerink Partners/ BMO Capital Markets
CO-Managers -
Expected To Trade: 6/21/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change